Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Sell
33
VRNA Quote, Financials, Valuation and Earnings
Last price:
$45.17
Seasonality move
:
-8.38%
Day range:
$45.84 - $49.30
52-week range:
$11.39 - $51.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
28.97x
Volume:
1.7M
Avg. volume:
1.1M
1-year change:
128.26%
Market cap:
$3.8B
Revenue:
--
EPS (TTM):
-$2.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$24.4M | -$0.24 | -- | -2.08% | $60.00 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$8.8M | -$0.15 | 4199.24% | -9.44% | $2.27 |
|
AUTL
Autolus Therapeutics PLC
|
$3M | -$0.24 | -61.82% | -46.14% | $10.45 |
|
BCYC
Bicycle Therapeutics PLC
|
$5.3M | -$0.86 | 0.18% | -26.16% | $33.91 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$46.20 | $60.00 | $3.8B | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.62 | $2.27 | $158.6M | -- | $0.00 | 0% | 0.87x |
|
AUTL
Autolus Therapeutics PLC
|
$2.41 | $10.45 | $641.4M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$14.17 | $33.91 | $978.4M | -- | $0.00 | 0% | 19.78x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$4.27 | $17.97 | $2.5M | -- | $0.00 | 0% | 3.85x |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.41 | -- | $3.3M | -- | $0.25 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
47.91% | -1.186 | 5.1% | 12.47x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 4.431 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.664 | -- | 17.97x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.994 | -- | 16.82x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.100 | -- | 1.20x |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.581 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$5.1M | -$39.1M | -55.17% | -74.15% | -583.75% | -$62.7M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$63.5M | -27.99% | -29.19% | -2026.05% | -$40.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
Verona Pharma PLC vs. Competitors
-
Which has Higher Returns VRNA or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of -43.07%. Verona Pharma PLC's return on equity of -74.15% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About VRNA or ADAP?
Verona Pharma PLC has a consensus price target of $60.00, signalling upside risk potential of 29.87%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $2.27 which suggests that it could grow by 265.65%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is VRNA or ADAP More Risky?
Verona Pharma PLC has a beta of 0.400, which suggesting that the stock is 60.012% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.236, suggesting its more volatile than the S&P 500 by 123.631%.
-
Which is a Better Dividend Stock VRNA or ADAP?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or ADAP?
Verona Pharma PLC quarterly revenues are $5.6M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Verona Pharma PLC's net income of -$43M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 0.87x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M ADAPAdaptimmune Therapeutics PLC0.87x -- $40.9M -$17.6M
-
Which has Higher Returns VRNA or AUTL?
Autolus Therapeutics PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of -522.15%. Verona Pharma PLC's return on equity of -74.15% beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About VRNA or AUTL?
Verona Pharma PLC has a consensus price target of $60.00, signalling upside risk potential of 29.87%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 333.61%. Given that Autolus Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Autolus Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is VRNA or AUTL More Risky?
Verona Pharma PLC has a beta of 0.400, which suggesting that the stock is 60.012% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.049, suggesting its more volatile than the S&P 500 by 104.921%.
-
Which is a Better Dividend Stock VRNA or AUTL?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or AUTL?
Verona Pharma PLC quarterly revenues are $5.6M, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Verona Pharma PLC's net income of -$43M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns VRNA or BCYC?
Bicycle Therapeutics PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of -1898.43%. Verona Pharma PLC's return on equity of -74.15% beat Bicycle Therapeutics PLC's return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M BCYCBicycle Therapeutics PLC-- -$0.74 $831M -
What do Analysts Say About VRNA or BCYC?
Verona Pharma PLC has a consensus price target of $60.00, signalling upside risk potential of 29.87%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $33.91 which suggests that it could grow by 135.45%. Given that Bicycle Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is VRNA or BCYC More Risky?
Verona Pharma PLC has a beta of 0.400, which suggesting that the stock is 60.012% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.586%.
-
Which is a Better Dividend Stock VRNA or BCYC?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or BCYC?
Verona Pharma PLC quarterly revenues are $5.6M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $2.7M. Verona Pharma PLC's net income of -$43M is higher than Bicycle Therapeutics PLC's net income of -$50.8M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 19.78x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M BCYCBicycle Therapeutics PLC19.78x -- $2.7M -$50.8M
-
Which has Higher Returns VRNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -74.15% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About VRNA or BDRX?
Verona Pharma PLC has a consensus price target of $60.00, signalling upside risk potential of 29.87%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 320.87%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is VRNA or BDRX More Risky?
Verona Pharma PLC has a beta of 0.400, which suggesting that the stock is 60.012% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.
-
Which is a Better Dividend Stock VRNA or BDRX?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or BDRX?
Verona Pharma PLC quarterly revenues are $5.6M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Verona Pharma PLC's net income of -$43M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 3.85x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M BDRXBiodexa Pharmaceuticals PLC3.85x -- -- --
-
Which has Higher Returns VRNA or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -74.15% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About VRNA or TCBP?
Verona Pharma PLC has a consensus price target of $60.00, signalling upside risk potential of 29.87%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 492.59%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Verona Pharma PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is VRNA or TCBP More Risky?
Verona Pharma PLC has a beta of 0.400, which suggesting that the stock is 60.012% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VRNA or TCBP?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Verona Pharma PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or TCBP?
Verona Pharma PLC quarterly revenues are $5.6M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Verona Pharma PLC's net income of -$43M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 10
IonQ [IONQ] is up 6.35% over the past day.
Sell
45
COLL alert for Jan 10
Collegium Pharmaceutical [COLL] is down 1.95% over the past day.
Sell
30
EDN alert for Jan 10
Empresa Distribuidora y Comercializadora Norte SA [EDN] is down 1.52% over the past day.
